NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CereVasc

CereVasc

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://cerevasc.com/

Last Round

Series C

Jun 4, 2026

Est. Valuation

$135M

Total Funding Raised

$198.9M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CereVasc is a medical device company that develops minimally invasive endovascular treatments for neurological diseases, including its flagship eShunt System for communicating hydrocephalus.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

medical deviceendovascular treatmenthydrocephalusbrain shuntminimally invasive surgeryidiopathic intracranial hypertensionneurosurgeryinterventional neuroradiologycerebrospinal fluid drainageimplantable medical deviceclinical trialsmedtechneurotechshunt alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CereVasc Comps

Public and private peers based on sector, stage, and business model.

CereVasc comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

CereVasc Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 4, 2026
Series BMay 13, 2024
Series AJun 9, 2020

Key People

Founding team and executive leadership

Adel Malek

Chief Medical Officer, Co-Founder

Founding Team

Daniel Levangie

President CEO

Executive Team

CereVasc Investors

Notable investors and investment history

CereVasc investors
InvestorRounds
Bain Capital Life SciencesSeries C, Series B
Perceptive AdvisorsSeries C, Series A, Series B
XontogenySeries B, Series A
Bain Capital, LPSeries B
Johnson & Johnson Innovation – JJDCSeries C
Johnson & Johnson Innovation - JJDC, Inc.Series C
ATON PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 4, 2026

    $85M round led by Piper Sandler & Co.

  • May 13, 2024

    $70M round led by Bain Capital, LP.

CereVasc Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CereVasc Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CereVasc's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range37
Year Founded2014
Last FundingJun 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.